Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QGEN
stocks logo

QGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
533.88M
+2.43%
0.598
-1.96%
509.89M
+5.47%
0.572
+4.08%
557.20M
+4.43%
0.639
+6.42%
Estimates Revision
The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.21% over the past three months. During the same period, the stock price has changed by -9.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.97%
In Past 3 Month
Stock Price
Go Down
down Image
-9.27%
In Past 3 Month
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 51.54 USD with a low forecast of 45.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 51.54 USD with a low forecast of 45.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 43.560
sliders
Low
45.00
Averages
51.54
High
60.00
Current: 43.560
sliders
Low
45.00
Averages
51.54
High
60.00
Baird
Outperform
to
NULL
downgrade
$49 -> $46
2025-11-06
New
Reason
Baird
Price Target
$49 -> $46
2025-11-06
New
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Qiagen to $46 from $49 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
TD Cowen
Dan Brennan
Hold
maintain
$49 -> $52
2025-08-07
Reason
TD Cowen
Dan Brennan
Price Target
$49 -> $52
2025-08-07
maintain
Hold
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Qiagen to $52 from $49 and keeps a Hold rating on the shares. Following a modest beat and raise print, the conference call was largely "steady as she goes," with CEO/CFO discussing ongoing traction with the growth of their 5 Pillars enhanced via numerous R&D initiatives, navigating through tariff margin pressures, and a consistent capital allocation strategy, the firm notes.
Berenberg
Sam England
Buy
maintain
2025-07-24
Reason
Berenberg
Sam England
Price Target
2025-07-24
maintain
Buy
Reason
Berenberg analyst Sam England raised the firm's price target on Qiagen to EUR 50 from EUR 48 and keeps a Buy rating on the shares.
Morgan Stanley
Equal Weight
maintain
2025-06-30
Reason
Morgan Stanley
Price Target
2025-06-30
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Qiagen to EUR 43 from EUR 42 and keeps an Equal Weight rating on the shares.
BofA
Buy
maintain
$50 -> $53
2025-06-26
Reason
BofA
Price Target
$50 -> $53
2025-06-26
maintain
Buy
Reason
BofA raised the firm's price target on Qiagen to $53 from $50 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.
Barclays
Luke Sergott
Overweight
initiated
$55
2025-06-24
Reason
Barclays
Luke Sergott
Price Target
$55
2025-06-24
initiated
Overweight
Reason
Barclays analyst Luke Sergott initiated coverage of Qiagen with an Overweight rating and $55 price target. The firm says Qiagen screens positive among tools given its exposure to diagnostics and higher growth genomics markets on the life sciences side. In the current macro and policy-driven space, Barclays favors diagnostics given the minimal exposure to headwinds plaguing the overall industry including biotech funding and pharma tariffs. On genomics, volumes in the business continue to be supported by cutting-edge research and increasingly by clinical applications like liquid biopsy, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Qiagen NV (QGEN.N) is 17.75, compared to its 5-year average forward P/E of 21.48. For a more detailed relative valuation and DCF analysis to assess Qiagen NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
21.48
Current PE
17.75
Overvalued PE
23.89
Undervalued PE
19.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
14.77
Current EV/EBITDA
12.25
Overvalued EV/EBITDA
16.28
Undervalued EV/EBITDA
13.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
5.36
Current PS
43.56
Overvalued PS
8.45
Undervalued PS
2.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 286.76% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

QGEN News & Events

Events Timeline

(ET)
2025-11-04
13:10:25
Qiagen increases FY25 adjusted EPS forecast to approximately $2.38, surpassing consensus of $2.37
select
2025-11-04
13:07:58
Qiagen Announces Q3 Adjusted EPS of 61 Cents, Exceeding Consensus Estimate of 59 Cents
select
2025-11-04
13:05:44
Qiagen to purchase Parse Biosciences for a total of up to $280 million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-05NASDAQ.COM
Transcript of Qiagen (QGEN) Q3 2025 Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
3.0
11-05NASDAQ.COM
Qiagen NV to Hold Q3 2025 Earnings Conference Call at 9:30 AM ET

  • Conference Call Announcement: Qiagen NV will hold a conference call on November 5, 2025, at 9:30 AM ET to discuss its Q3 2025 earnings results.

  • Access Information: The live webcast can be accessed through a provided link, and listeners can join the call by dialing specific phone numbers with a conference ID.

[object Object]
Preview
9.5
11-05NASDAQ.COM
Qiagen NV Sees Increase in Q3 Profit

  • Third-Quarter Financial Performance: Qiagen NV reported a net income of $130 million or $0.60 per share for the third quarter, an increase from $98 million or $0.44 per share the previous year.

  • Adjusted Earnings: The company’s adjusted earnings for the quarter were $133 million or $0.61 per share, reflecting strong performance excluding certain items.

  • Revenue Growth: Qiagen's revenue rose by 6.2% to $533 million, up from $502 million in the same quarter last year.

  • Future Earnings Outlook: The company has revised its full-year 2025 adjusted earnings per share forecast to approximately $2.38, an increase from the previous estimate of $2.35.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Qiagen NV (QGEN) stock price today?

The current price of QGEN is 43.56 USD — it has increased 1.16 % in the last trading day.

arrow icon

What is Qiagen NV (QGEN)'s business?

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

arrow icon

What is the price predicton of QGEN Stock?

Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 51.54 USD with a low forecast of 45.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Qiagen NV (QGEN)'s revenue for the last quarter?

Qiagen NV revenue for the last quarter amounts to 532.58M USD, increased 6.12 % YoY.

arrow icon

What is Qiagen NV (QGEN)'s earnings per share (EPS) for the last quarter?

Qiagen NV. EPS for the last quarter amounts to 0.60 USD, increased 33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Qiagen NV (QGEN)'s fundamentals?

The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.21% over the past three months. During the same period, the stock price has changed by -9.27%.
arrow icon

How many employees does Qiagen NV (QGEN). have?

Qiagen NV (QGEN) has 5765 emplpoyees as of November 09 2025.

arrow icon

What is Qiagen NV (QGEN) market cap?

Today QGEN has the market capitalization of 9.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free